Withdrawal of Heidi Overton's FDA Nomination Cited as Reason for Lack of Support on Capitol Hill
The White House has unexpectedly pulled its nomination for Heidi Overton to lead the Food and Drug Administration, ending her contentious bid for the position just hours after it was announced.

The White House has unexpectedly pulled its nomination for Heidi Overton to lead the Food and Drug Administration, ending her contentious bid for the position just hours after it was announced.
Overton's selection had been met with widespread criticism from both Republicans and Democrats due to her stances on various public health issues. Her views on vaccines, abortion, vaping products, and birth control have raised concerns among lawmakers who are expected to scrutinize any nominee closely.
In her confirmation hearing last September, Overton refused to answer several key questions from senators, leaving many frustrated with her evasive responses. Despite being asked by friendly Republicans about the FDA's review of the abortion pill mifepristone, she failed to provide a clear stance on the matter.
Her inability to directly address these issues has sparked debate over whether she is qualified for the role and whether she would be able to effectively lead the agency. Critics argue that her stances are at odds with widely accepted scientific consensus on public health matters.
The withdrawal of Overton's nomination marks another setback for the Trump administration, which had hoped to see its nominee confirmed before the end of the year. The sudden change in plans has left many wondering about the future of the FDA and who will ultimately be chosen to lead it.
The sudden withdrawal of Dr. Rachel Overton's nomination has left many wondering about the fate of the FDA leadership position.
According to Axios, a senior Trump administration official cited a lack of support on Capitol Hill as the reason for Overton's nomination being dropped.
The Senate's Health, Education, Labor and Pensions Committee was set to vote on her confirmation Wednesday, but that is now off the table. In fact, just hours before the scheduled vote, Chairman Bill Cassidy posted on social media that he believed a confirmation path existed for Overton.
However, Cassidy also revealed that some anti-abortion senators had sought commitments from Overton that they couldn't obtain, leading the administration to withdraw her nomination.
As a result of this development, Cassidy noted that confirming a permanent FDA Commissioner will now fall to Senate Democrats with limited time left.
The HELP committee has updated its agenda for Wednesday to scrap a scheduled vote on Jim O'Neill, who was Trump's nominee to run the NSF.
The HELP committee has made a significant adjustment to its agenda for Wednesday, cancelling a scheduled vote on Jim O'Neill's nomination to run the NSF. This decision comes after Cassidy expressed concerns about O'Neill's stance on science and his handling of certain situations during his tenure. Specifically, Cassidy pointed out that O'Neill was involved in the termination of Monarez, which raised eyebrows among several members of the committee.
Cassidy emphasized that this moment requires strong leadership and a willingness to stand up for what is right, even when it's challenging. He made it clear that simply going through the motions or prioritizing other interests over scientific integrity would not suffice.
The NSF has faced intense pressure from the Trump administration in recent years, with devastating consequences. The agency has had to cancel numerous research grants and undergo severe budget cuts, affecting its ability to fund vital projects. Furthermore, the Trump administration terminated all members of the National Science Board, sparking fears that O'Neill's appointment would allow for a politicized takeover of the NSF.
The cancellation of the vote on O'Neill's nomination is a significant setback for the Trump administration, which had been pushing for his confirmation. The decision reflects growing concerns about the administration's handling of scientific research and its willingness to prioritize politics over expertise.
Facts based on reporting originally published by Ars Technica.
You may republish this story, in full or in part, if you credit Noti Group and link to it (licence CC BY 4.0). Photos are not included.












